Arthritis Rheum:感染牙龈卟啉单胞菌或增加罹患RA风险

2013-01-06 Arthritis Rheum 中华风湿网

  目的:旨在探讨牙龈卟啉单胞菌与类风湿关节炎(RA)高风险人群出现自身抗体之间的关系。   方法:研究对象包括:1)携带HLA-DR4的人群和2)一级亲属为RA患者的RA高风险人群。所有这些研究对象均不符合1987年ACR的RA分类标准。需检测的自身抗体包括抗瓜氨酸化蛋白抗体(ACPA;ELISA法)和类风湿因子(RF;浊度测定法或ELISA法检测IgA,IgM或IgG亚型抗体)。检测到

  目的:旨在探讨牙龈卟啉单胞菌与类风湿关节炎(RA)高风险人群出现自身抗体之间的关系。

  方法:研究对象包括:1)携带HLA-DR4的人群和2)一级亲属为RA患者的RA高风险人群。所有这些研究对象均不符合1987年ACR的RA分类标准。需检测的自身抗体包括抗瓜氨酸化蛋白抗体(ACPA;ELISA法)和类风湿因子(RF;浊度测定法或ELISA法检测IgA,IgM或IgG亚型抗体)。检测到>1个RA相关自身抗体的个体被认为是自身抗体阳性个体(n=113);如ACPA或>2实验检测的RF阳性个体可被进一步分类为RA的高危人群(n=38)。自身抗体阴性的个体作为对照组(n=171)。检测抗牙龈卟啉单胞菌、中间普雷沃菌、具核梭杆菌抗体。应用逻辑回归的方式评估细菌抗体与不同分组之间的相关性。

  结果:自身抗体阳性组和RA高风险组中抗牙龈卟啉单胞菌抗体的浓度高于自身抗体阴性组。抗中间普雷沃菌抗体或抗具核梭杆菌抗体浓度在各组间均没有差异。经多变量调整后抗牙龈卟啉单胞菌抗体的浓度(而不是抗中间普雷沃菌抗体或抗具核梭杆菌抗体)与自身抗体阳性和RA高风险状态显著相关。

  结论:牙龈卟啉单胞菌的免疫原性与RA高风险人群中RA相关性自身抗体的出现显著相关。这些结果支持了这一假说:牙龈卟啉单胞菌的感染在RA发病早期的自身抗原免疫失耐受过程中发挥了重要作用。


Porphyromonas gingivalis and disease-related autoantibodies in individuals at increased risk of rheumatoid arthritis

Objective

To examine the relationship of Porphyromonas gingivalis to the presence of autoantibodies in individuals at risk of rheumatoid arthritis (RA).

Methods

Study participants included the following: 1) a cohort enriched in subjects with HLA–DR4 and 2) subjects at risk of RA by virtue of having a first-degree relative with RA. None of the study subjects satisfied the American College of Rheumatology 1987 classification criteria for RA. Autoantibodies measured included anti–citrullinated protein antibody (ACPA; by second-generation anti–cyclic citrullinated peptide antibody enzyme-linked immunosorbent assay [ELISA]) and rheumatoid factor (RF; by nephelometry or ELISA for IgA, IgM, or IgG isotype). Individuals were considered autoantibody positive (n = 113) if they had ≥1 RA-related autoantibody; individuals were further categorized as high risk (n = 38) if they had ACPA or positive findings ≥2 assays for RF. Autoantibody-negative individuals (n = 171) served as a comparator group. Antibody to P gingivalis, P intermedia, and F nucleatum were measured. Associations of bacterial antibodies with group status were examined using logistic regression.

Results

Anti–P gingivalis concentrations were higher in high-risk (P = 0.011) and autoantibody positive group (P = 0.010) than in the autoantibody negative group. There were no group differences in anti–P intermedia or anti–F nucleatum concentrations. After multivariable adjustment, anti–P gingivalis concentrations (but not anti–P intermedia or anti–F nucleatum) were significantly associated with autoantibody-positive and high-risk status (P < 0.05).

Conclusion

Immunity to P gingivalis, but not P intermedia or F nucleatum, is significantly associated with the presence of RA-related autoantibodies in individuals at risk of RA. These results support the hypothesis that infection with P gingivalis may play a central role in the early loss of tolerance to self antigens that occurs in the pathogenesis of RA.

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1972318, encodeId=503c19e23183a, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Sep 03 03:19:00 CST 2013, time=2013-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355718, encodeId=5e9b1355e18a0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jan 08 04:19:00 CST 2013, time=2013-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361028, encodeId=eea2136102836, content=<a href='/topic/show?id=c1006e72663' target=_blank style='color:#2F92EE;'>#牙龈卟啉单胞菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67726, encryptionId=c1006e72663, topicName=牙龈卟啉单胞菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Tue Jan 08 04:19:00 CST 2013, time=2013-01-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1972318, encodeId=503c19e23183a, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Sep 03 03:19:00 CST 2013, time=2013-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355718, encodeId=5e9b1355e18a0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jan 08 04:19:00 CST 2013, time=2013-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361028, encodeId=eea2136102836, content=<a href='/topic/show?id=c1006e72663' target=_blank style='color:#2F92EE;'>#牙龈卟啉单胞菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67726, encryptionId=c1006e72663, topicName=牙龈卟啉单胞菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Tue Jan 08 04:19:00 CST 2013, time=2013-01-08, status=1, ipAttribution=)]
    2013-01-08 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1972318, encodeId=503c19e23183a, content=<a href='/topic/show?id=8a6a2e8839' target=_blank style='color:#2F92EE;'>#Arthritis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2788, encryptionId=8a6a2e8839, topicName=Arthritis)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Tue Sep 03 03:19:00 CST 2013, time=2013-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355718, encodeId=5e9b1355e18a0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jan 08 04:19:00 CST 2013, time=2013-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361028, encodeId=eea2136102836, content=<a href='/topic/show?id=c1006e72663' target=_blank style='color:#2F92EE;'>#牙龈卟啉单胞菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67726, encryptionId=c1006e72663, topicName=牙龈卟啉单胞菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Tue Jan 08 04:19:00 CST 2013, time=2013-01-08, status=1, ipAttribution=)]

相关威廉亚洲官网

FDA批准tofacitinib治疗类风湿关节炎

  2012年11月6日,美国食品与药物管理局(FDA)通过危险评估和减轻策略(REMS)批准了JAK抑制剂tofacitinib用于治疗成人活动期及对甲氨蝶呤(MTX)反应不佳的中至重度类风湿关节炎(RA)患者,该药每日服用两次,5mg/次。   7项纳入中至重度活动期RA成人患者的临床试验评估了tofacitinib的安全性和有效性。这些实验均表明,与安慰剂组相比,接受tofacitinib

ACR:抗TNF药物治疗RA患者第1年严重感染发生风险高

  日本学者研究发现,在连续使用抗肿瘤坏死因子(TNF)药物治疗类风湿关节炎(RA)的过程中,仅有第1年的治疗与患者发生严重感染的风险增加显著相关,而在治疗的第2或第3年此相关性消失。论文发表于《关节炎护理与研究》杂志[Arthritis Care Res 2012,64(8):1125]。   研究纳入起始接受英夫利昔单抗或依那西普(抗TNF组)治疗的RA患者72

FDA批准第一个治疗类风湿关节炎口服生物制剂Xeljanz

美国食品和药物管理局(FDA)于11月6日批准辉瑞公司新药Xeljanz用于治疗类风湿性关节炎,Xeljanz是该公司最具有市场前景的实验性药物之一,未来将与雅培公司的修美乐(Humira)形成竞争。在这之前,FDA宣布延长对该药的审查期(8月23日) FDA表示,中到重度的类风湿性关节炎病人,无法从常规口服治疗药物甲氨蝶呤(methotrexate)中获益或无法耐受治疗时,可使用辉瑞的新药Xe

ARD:抑制粒细胞-巨噬细胞集落刺激因子治疗类风湿关节炎和骨关节炎

最新一项研究发现粒细胞巨噬细胞集落刺激因子GM-CSF在炎症部位的细胞之间的信号使者。 在该研究中,教授John Hamilton提出了一个问题:阻断GM-CSF能否是炎症性疾病一种新的治疗方法?在类风湿关节炎的实验模型,Hamilton博士和Andrew Cook教授曾表明用抗体阻断GM-CSF的功能能抑制疾病的发展,这一作用已在临床试验中显示出一定的效果。 他们发表在Annals of t

Arthritis Rheum:TNFi类型不影响RA患者死亡率

  瑞典学者研究发现,在接受依那西普、英夫利昔单抗和阿达木单抗等不同种类肿瘤坏死因子抑制剂(TNFi)治疗的类风湿关节炎(RA)患者中,死亡率无显著差异;英夫利昔单抗相对于依那西普的风险比(HR)为1.1,阿达木单抗相对于依那西普的HR为1.3。论文发表于《关节炎与风湿病》[Arthritis Rheum 2012,64:3502]杂志。

ACR 2012年会:类风湿关节炎患者可发生痛风

  华盛顿——在美国风湿病学会(ACR)年会上,Adlene Jebakumar博士报告的一项人群队列研究显示,类风湿性关节炎(RA)患者确实可发生痛风,只不过发生率低于一般人群。         Eric L. Matteson博士   这项研究纳入813例1980~2007年被诊断为RA的患者。根据临床标准(包括滑液中检出典型尿酸单钠晶体)或ACR前身美国